Simulations Plus Hosts Virtual Investor Day Showcasing AI-Driven Drug Development Strategy

Reuters12-18 20:50
<a href="https://laohu8.com/S/SLP">Simulations Plus</a> Hosts Virtual Investor Day Showcasing AI-Driven Drug Development <a href="https://laohu8.com/S/MSTR">Strategy</a>

Simulations Plus Inc., a leader in model-informed and AI-accelerated drug development, will host a virtual Investor Day on Wednesday, January 21, 2026. The event will provide investors and analysts with insights into the company’s long-term strategy, product roadmap, and financial outlook, featuring presentations from the executive leadership team. The agenda includes updates on industry trends, advances in scientific services, and the company’s unified technology strategy. The event will be webcast live, with a replay available afterward.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Simulations Plus Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251218867761) on December 18, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment